12,13-diHOME as a new therapeutic target for metabolic diseases

Life Sci. 2022 Feb 1:290:120229. doi: 10.1016/j.lfs.2021.120229. Epub 2021 Dec 14.

Abstract

Lipokines are bioactive compounds, derived from adipose tissue depots, that control several molecular signaling pathways. Recently, 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME), an oxylipin, has gained prominence in the scientific literature. An increase in circulating 12,13-diHOME has been associated with improved metabolic health, and the action of this molecule appears to be mediated by brown adipose tissue (BAT). Scientific evidence indicates that the increase in serum levels of 12,13-diHOME caused by stimuli such as physical exercise and exposure to cold may favor the absorption of fatty acids by brown adipose tissue and stimulate the browning process in white adipose tissue (WAT). Thus, strategies capable of increasing 12,13-diHOME levels may be promising for the prevention and treatment of obesity and metabolic diseases. This review explores the relationship of 12,13-diHOME with brown adipose tissue and its role in the metabolic health context, as well as the signaling pathways involved between 12,13-diHOME and BAT.

Keywords: 12,13-diHOME; Batokines; Browning; Chronic diseases; Lipid mediators.

Publication types

  • Review

MeSH terms

  • Adipose Tissue, Brown / metabolism*
  • Adipose Tissue, White / metabolism
  • Humans
  • Metabolic Diseases / drug therapy*
  • Metabolic Diseases / metabolism*
  • Molecular Targeted Therapy
  • Oleic Acids / blood
  • Oleic Acids / metabolism*
  • Oleic Acids / pharmacology
  • Oxylipins / metabolism

Substances

  • 12,13-dihydroxyoctadecenoic acid
  • Oleic Acids
  • Oxylipins